Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
REGENXBIO to Present at the 39th Annual J.P. Morgan Healthcare Conference
07:05am, Monday, 11'th Jan 2021
ROCKVILLE, Md., Jan. 11, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 11:40
REGENXBIO Announces Pricing Of Public Offering Of Common Stock
07:05am, Friday, 08'th Jan 2021
ROCKVILLE, Md., Jan. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 4,260,000 shares of its common stock at the price of $47.00
REGENXBIO (RGNX) Provides Update on RGX-314 & Begins New Program
12:02pm, Wednesday, 06'th Jan 2021
REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy
REGENXBIO Announces Agreement to Monetize Portion of Zolgensma® Royalties for $200 Million
04:19pm, Tuesday, 22'nd Dec 2020
ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy base
Regenxbio: Championing Gene Therapy
08:55am, Saturday, 19'th Dec 2020
Back in 2019, the Zolgensma approval validated Regenxbio's NAV technology platform for gene delivery. Despite a slow start, Zolgensma recently hit $1B in cumulative sales. Regenxbio's organic pipeline
4 Biotechs That Could Be Potential Acquisition Targets in 2021
10:32am, Thursday, 17'th Dec 2020
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
ROCKVILLE, Md., Dec. 10, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy base
REGENXBIO Announces Dosing of First Patient in Phase I/II Trial of RGX-111 for the Treatment of Mucopolysaccharidosis Type I
07:05am, Tuesday, 01'st Dec 2020
ROCKVILLE, Md., Dec. 1, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based
REGENXBIO to Present at Upcoming Investor Conferences
04:05pm, Monday, 23'rd Nov 2020
ROCKVILLE, Md., Nov. 23, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy base
REGENXBIO, Inc. (RGNX) CEO Ken Mills on Q3 2020 Results - Earnings Call Transcript
12:01am, Thursday, 05'th Nov 2020
REGENXBIO, Inc. (RGNX) CEO Ken Mills on Q3 2020 Results - Earnings Call Transcript
Recap: Regenxbio Q3 Earnings
05:27pm, Wednesday, 04'th Nov 2020
Shares of Regenxbio (NASDAQ:RGNX) were flat after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 124.47% over the past year to $0.23, which beat
